The safety of rosiglitazone in the treatment of type 2 diabetes

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579.

Abstract

Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease.

Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone.

Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers.

Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Blood Glucose / drug effects
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Fractures, Bone / chemically induced
  • Heart Failure / chemically induced
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use
  • Myocardial Infarction / chemically induced
  • Risk Factors
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • Thiazolidinediones / therapeutic use

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone